These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity. Badimon JJ; Weng D; Chesebro JH; Fuster V; Badimon L Thromb Haemost; 1994 Apr; 71(4):511-6. PubMed ID: 8052972 [TBL] [Abstract][Full Text] [Related]
4. The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs. Kogushi M; Matsuoka T; Kawata T; Kuramochi H; Kawaguchi S; Murakami K; Hiyoshi H; Suzuki S; Kawahara T; Kajiwara A; Hishinuma I Eur J Pharmacol; 2011 Apr; 657(1-3):131-7. PubMed ID: 21300059 [TBL] [Abstract][Full Text] [Related]
5. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition. Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274 [TBL] [Abstract][Full Text] [Related]
6. Antithrombotic properties of pravastatin reducing intra-thrombus fibrin deposition under high shear blood flow conditions. Hamada M; Sugimoto M; Matsui H; Mizuno T; Shida Y; Doi M; Fukushima H; Nishio K; Yoshioka A; Shima M Thromb Haemost; 2011 Feb; 105(2):313-20. PubMed ID: 21136018 [TBL] [Abstract][Full Text] [Related]
7. Genetic strain differences in platelet aggregation and thrombus formation of laboratory rats. Sudo T; Ito H; Hayashi H; Nagamura Y; Toga K; Yamada Y Thromb Haemost; 2007 Apr; 97(4):665-72. PubMed ID: 17393031 [TBL] [Abstract][Full Text] [Related]
8. [Effects of 3-n-butylphthalide on thrombosis formation and platelet function in rats]. Xu HL; Feng YP Yao Xue Xue Bao; 2001 May; 36(5):329-33. PubMed ID: 12584852 [TBL] [Abstract][Full Text] [Related]
9. Biological properties of a specific Galpha q/11 inhibitor, YM-254890, on platelet functions and thrombus formation under high-shear stress. Uemura T; Kawasaki T; Taniguchi M; Moritani Y; Hayashi K; Saito T; Takasaki J; Uchida W; Miyata K Br J Pharmacol; 2006 May; 148(1):61-9. PubMed ID: 16520742 [TBL] [Abstract][Full Text] [Related]
10. New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent. Badorc A; Bordes MF; de Cointet P; Savi P; Bernat A; Lalé A; Petitou M; Maffrand JP; Herbert JM J Med Chem; 1997 Oct; 40(21):3393-401. PubMed ID: 9341914 [TBL] [Abstract][Full Text] [Related]
11. Neferine exerts its antithrombotic effect by inhibiting platelet aggregation and promoting dissociation of platelet aggregates. Zhou YJ; Xiang JZ; Yuan H; Liu H; Tang Q; Hao HZ; Yin Z; Wang J; Ming ZY Thromb Res; 2013 Aug; 132(2):202-10. PubMed ID: 23773522 [TBL] [Abstract][Full Text] [Related]
12. Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor. Kageyama S; Yamamoto H; Nagano M; Arisaka H; Kayahara T; Yoshimoto R Br J Pharmacol; 1997 Sep; 122(1):165-71. PubMed ID: 9298543 [TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of novel biologically active thrombin receptor non-peptide mimetics based on the pharmacophoric cluster Phe/Arg/NH2 of the Ser42-Phe-Leu-Leu-Arg46 motif sequence: platelet aggregation and relaxant activities. Alexopoulos K; Fatseas P; Melissari E; Vlahakos D; Roumelioti P; Mavromoustakos T; Mihailescu S; Paredes-Carbajal MC; Mascher D; Matsoukas J J Med Chem; 2004 Jun; 47(13):3338-52. PubMed ID: 15189031 [TBL] [Abstract][Full Text] [Related]
14. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design. Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442 [TBL] [Abstract][Full Text] [Related]
15. Antiplatelet and antithrombotic activities of CP201, a newly synthesized 1,4-naphthoquinone derivative. Jin YR; Hwang KA; Cho MR; Kim SY; Kim JH; Ryu CK; Son DJ; Park YH; Yun YP Vascul Pharmacol; 2004 Feb; 41(1):35-41. PubMed ID: 15135330 [TBL] [Abstract][Full Text] [Related]
16. Antiaggregating and antithrombotic activities of new 1, 2, 3-triazolecarboxamides. Cwiklicki A; Rehse K Arch Pharm (Weinheim); 2004 Mar; 337(3):156-63. PubMed ID: 15038061 [TBL] [Abstract][Full Text] [Related]
17. Protein disulphide isomerase-mediated LA419- NO release provides additional antithrombotic effects to the blockade of the ADP receptor. Vilahur G; Pena E; Padró T; Badimon L Thromb Haemost; 2007 Apr; 97(4):650-7. PubMed ID: 17393029 [TBL] [Abstract][Full Text] [Related]